Butyrate ( DrugBank: Butyrate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 2 |
| 97 | Ulcerative colitis | 2 |
| 156 | Rett syndrome | 1 |
| 291 | Hirschsprung disease, entire colon type | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05718583 (ClinicalTrials.gov) | February 1, 2023 | 30/1/2023 | Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders | A Pilot Proof of Concept Study of the Effects of Administration of a Short Chain Fatty Acid (SCFA) Supplement in Rheumatoid Arthritis Inadequate Responders (EASi-RAIR) | Rheumatoid Arthritis | Dietary Supplement: Butyrate | NYU Langone Health | Arthritis Foundation | Recruiting | 18 Years | N/A | All | 35 | N/A | United States |
| 2 | NCT05576597 (ClinicalTrials.gov) | August 23, 2022 | 7/10/2022 | Effect of Butyrate Supplement on Rheumatoid Arthritis | A Pilot Study to Evaluate Efficacy and Safety of Butyrate Supplement in the Treatment of Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Sodium Butyrate | Peking University People's Hospital | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | China |
97. Ulcerative colitis
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05218850 (ClinicalTrials.gov) | July 1, 2022 | 20/1/2022 | The Use of Butyrate Therapy in Pediatric Ulcerative Colitis | Butyrate Therapy in Pediatric Ulcerative Colitis | Ulcerative Colitis | Drug: Butyrate | Children's Hospital Los Angeles | NULL | Not yet recruiting | 7 Years | 21 Years | All | 10 | Phase 1 | United States |
| 2 | NCT04259060 (ClinicalTrials.gov) | June 2020 | 27/1/2020 | Hydroxocobalamin Approach to Reduction of Calprotectin With Butyrate for Ulcerative Colitis Research | Hydroxocobalamin Approach to Reduction of Nitrite With Butyrate for Ulcerative Colitis | Ulcerative Colitis | Drug: Hydroxocobalamin with Butyrate;Drug: Placebo with Butyrate | Joshua Korzenik | NULL | Not yet recruiting | 18 Years | 75 Years | All | 42 | Phase 2 | United States |
156. Rett syndrome
Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05420805 (ClinicalTrials.gov) | April 1, 2022 | 13/6/2022 | Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT) | Protective Effects of Pre- and Post-biotics on Gut Inflammation, Microbiota Diversity, Epileptogenesis, and Quality of Life in Rett Syndrome | Rett Syndrome;Dysbiosis;Epilepsy;Quality of Life | Dietary Supplement: ALAC, inulin, FOS, and sodium butyrate;Dietary Supplement: Sodium butyrate and zinc oxide | Azienda Ospedaliera Universitaria Senese | Kolfarma s.r.l. - Italy;European Institute of Oncology | Recruiting | 3 Years | N/A | Female | 30 | N/A | Italy |
291. Hirschsprung disease, entire colon type
Clinical trials : 12 / Drugs : 24 - (DrugBank : 15) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03660176 (ClinicalTrials.gov) | January 2, 2019 | 4/9/2018 | Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung's Disease | Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung's | Hirschsprung's Disease | Drug: butyrate enemas + routine management;Other: routine management | Assistance Publique Hopitaux De Marseille | NULL | Not yet recruiting | N/A | 17 Years | All | 58 | Phase 3 | France |